{"ticker": {"uuid": "b50f14e7-0fd9-4ffd-a5aa-264a8d57dc42", "symbol": "EYPT", "name": "Eyepoint Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Stifel initiates EyePoint stock with buy rating on retinal drug potential", "summary": "Stifel has initiated coverage on EyePoint Inc. with a buy rating and a $40.00 price target, citing the potential of its sustained-delivery retinal disease treatment, Duravyu. The drug is expected to offer extended treatment intervals for patients with retinal diseases and its piv", "url": "https://www.investing.com/news/analyst-ratings/stifel-initiates-eyepoint-stock-with-buy-rating-on-retinal-drug-potential-93CH-4794362", "source_name": "Investing.com", "published_at": "2026-07-16T04:54:00", "published_display": "16 Jul 2026 04:54", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint, Inc. (EYPT) CEO exercises RSUs, with shares withheld for taxes", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPczJfdWZfcGJ4WnpCUjBUdDF5Z0xUQ09jX2JwcWdpOTFoZ0xBYUh4LXVOWHpUY3VpZG51a2ZNTnBHdmtoVWV1eHRTTDhZS1dlamFsLWgycks1YXgyekZXT2U2MEdiVUZ0Y2pyQUY5VlZ3YnpYekN0c1hGbjBGbW1zVGU4eTgzcTI1cTZTdDd1NzBaSDFqRnR6cUdTakV4X3pmOVdXUXlXTjFHSGs?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T20:08:19+00:00", "published_display": "14 Jul 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer", "summary": "EyePoint, Inc. appointed Tarek S. Hassan, M.D., a globally renowned retina specialist, as their Chief Strategic Science Officer. Dr. Hassan will provide strategic guidance for the company's clinical development, commercialization, and pipeline initiatives, particularly for their ", "url": "https://www.globenewswire.com/news-release/2026/07/13/3326057/0/en/eyepoint-appoints-tarek-s-hassan-m-d-as-chief-strategic-science-officer.html", "source_name": "GlobeNewswire", "published_at": "2026-07-14T04:42:14", "published_display": "14 Jul 2026 04:42", "sentiment": "positive", "sentiment_pct": 75, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint (EYPT) Adds Retina Leadership, Is The 64% Undervaluation Case Convincing?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-13T17:33:50+00:00", "published_display": "13 Jul 2026 17:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho Securities Maintains EyePoint(EYPT.US) With Buy Rating, Maintains Target Price $36", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQeWJSZVowMnFXSFR5ZEx3aGYyd1VPNVVQQ0doU2VXRXEtWGZGb2QwWGFaZDVuVTlFaE9YQ2V3aEYxTldDR0xIUWlRcTVJWkVUd05hMTJ6UDhrNTlnRTIzV1NiRXRkSHZZNzNZNjJGbW1vRWE3QS00ZE4yZTJjZ2R2VzZMNkxVcGMtS3RUUzFGbUhNQWdiWWUzbGdUeUlsN2Y1M3liNEpOZmJkZlQwZ2pjb1N6U2JBU2l1R3c?oc=5", "source_name": "Moomoo", "published_at": "2026-07-13T13:34:00+00:00", "published_display": "13 Jul 2026 13:34", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Renowned retina specialist Tarek S. Hassan joins EyePoint ahead of key DURAVYU trial readout", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQdEhfcEZkSUFxOGZkM3ZxM1ItUHpibmRGQWlLeWU4QnZ2TjEyWWFodWZyN2tUWUdqanJlS3ZjMXhfYzZJNkg3TFNOS2UyQ1o0YmVsY3pfUzRldXRzME9iNW1OYUo2M1RLNEpjRzdJNHd6VTZfb0ZROGpyWUZFenVjb2NMTW5lUTNpSFNYa2VJMUtkZVQ3NnVNSUZDajlwOGFVek5malhmaUtyLVVWdk9ET0k5eVhqRFN1c2xF?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T11:00:00+00:00", "published_display": "13 Jul 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does EyePoint\u2019s (EYPT) Broad Russell Index Debut Quietly Recast Its DURAVYU\u2011Centric Investor Base?", "summary": "EyePoint (EYPT) was recently added to several Russell growth and small-cap indices, increasing its visibility to index-tracking investors. While this broadens exposure, the company's investment narrative still heavily relies on the success of its single asset, DURAVYU, with criti", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint/news/does-eyepoints-eypt-broad-russell-index-debut-quietly-recast/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-10T16:10:10", "published_display": "10 Jul 2026 16:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint Pharmaceuticals Coverage Assumed by Cantor Fitzgerald at Overweight", "summary": "Cantor Fitzgerald has initiated coverage on EyePoint Pharmaceuticals (NASDAQ: EYPT) with an Overweight rating. The firm set a price target of $24.00 for the pharmaceutical company.", "url": "https://www.moomoo.com/news/post/72654158/eyepoint-pharmaceuticals-coverage-assumed-by-cantor-fitzgerald-at-overweight", "source_name": "Moomoo", "published_at": "2026-07-09T03:10:10", "published_display": "09 Jul 2026 03:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint Pharmaceuticals updates its strategy as retinal pipeline advances", "summary": "EyePoint Pharmaceuticals is updating its strategy as its pipeline of long-acting eye therapies for retinal diseases advances. The company specializes in sustained intraocular drug delivery, aiming to reduce treatment burden for patients. Its focus is on developing proprietary imp", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/eyepoint-pharmaceuticals-updates-its-strategy-as-retinal-pipeline-advances/69726713", "source_name": "Ad Hoc News", "published_at": "2026-07-09T03:09:47", "published_display": "09 Jul 2026 03:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price-Driven Insight from (EYPT) for Rule-Based Strategy", "summary": "This article provides a price-driven analysis for Eyepoint Pharmaceuticals Inc. (NASDAQ: EYPT), indicating a near-term neutral sentiment amidst mid and long-term strength. It outlines various AI-generated trading strategies including position, momentum breakout, and risk hedging,", "url": "https://news.stocktradersdaily.com/news_release/24/Price-Driven_Insight_from_EYPT_for_Rule-Based_Strategy_070726063802_1783420682.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-07T06:38:51", "published_display": "07 Jul 2026 06:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint shared additions to scientific advisory board and conditional approval of trade name for EYP-1901", "summary": "EyePoint Pharmaceuticals has expanded its Scientific Advisory Board by appointing three leading ophthalmologists: Usha Chakravarthy, Allen Ho, and Frank Holz. These additions will support the company's global clinical strategy as it prepares for Phase 3 trials for wet age-related", "url": "https://www.ophthalmologytimes.com/view/eyepoint-shared-additions-to-scientific-advisory-board-and-conditional-approval-of-trade-name-for-eyp-1901", "source_name": "Ophthalmology Times Europe", "published_at": "2026-07-07T03:10:10", "published_display": "07 Jul 2026 03:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s Why EyePoint, Inc. (EYPT) Is Among the Best Get Rich Quick Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQTl9faU9Kd2RlckhrZEg0cFBhSDQzaVFKaW5nWkVkXzVOci1VUGxOME5xc1dzM2pvcl9iaHFEZFgwOHFwNXozMFZVNU00R0ZVU0hnaDRBOFB4Q2lGV3QwazlpaENrY1pPMGJMOGwtcGFCR0ZZUFJFcVZzY3dnYzhHMGx2OWJMQ2puR3c0UFhaT1dZR09tTmxn?oc=5", "source_name": "Market source", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Guggenheim reiterates Buy on EyePoint stock, cites trial progress", "summary": "Guggenheim has reiterated a Buy rating on EyePoint Inc. (NASDAQ:EYPT) with a $68.00 price target, citing promising progress in the company's clinical trials for wet age-related macular degeneration and diabetic macular edema. Enrollment is complete for the LUGANO and LUCIA trials", "url": "https://www.investing.com/news/analyst-ratings/guggenheim-reiterates-buy-on-eyepoint-stock-cites-trial-progress-93CH-4666411", "source_name": "Investing.com", "published_at": "2026-07-06T02:10:36", "published_display": "06 Jul 2026 02:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint Pharmaceuticals outlines long-term retina strategy as a specialty biotech", "summary": "EyePoint Pharmaceuticals is a specialty biopharmaceutical company focused on developing sustained drug delivery technologies for serious retinal diseases. The company aims to address the burden of frequent treatments for conditions like age-related macular degeneration by providi", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/eyepoint-pharmaceuticals-outlines-long-term-retina-strategy-as-a-specialty/69682599", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T19:09:13", "published_display": "03 Jul 2026 19:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint (EYPT) Joins Russell Growth Indices, Is The Stock Still Undervalued?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-03T12:29:46+00:00", "published_display": "03 Jul 2026 12:29", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Eyepoint Pharmaceuticals Inc For: 2 July By Investing.com", "summary": "This article reports on a Form 4 filing for Eyepoint Pharmaceuticals Inc. for transactions that occurred on July 2nd. It is a brief announcement from Investing.com and does not contain further details within the main body. The article is surrounded by various financial market dat", "url": "https://ca.investing.com/news/stock-market-news/form-4-eyepoint-pharmaceuticals-inc-for-2-july-93CH-4718918", "source_name": "Investing.com Canada", "published_at": "2026-07-02T20:42:31", "published_display": "02 Jul 2026 20:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint CMO Ramiro Ribeiro sells $73,166 in company stock", "summary": "EyePoint, Inc.'s Chief Medical Officer, Ramiro Ribeiro, recently sold 4,875 shares of company stock, totaling approximately $73,166, after exercising stock options. Following these transactions, Ribeiro holds no direct shares but retains 153,564 stock options. The company is repo", "url": "https://www.investing.com/news/insider-trading-news/eyepoint-cmo-ramiro-ribeiro-sells-73166-in-company-stock-93CH-4774038", "source_name": "Investing.com", "published_at": "2026-07-02T20:40:38", "published_display": "02 Jul 2026 20:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint CMO Ramiro Ribeiro sells $73,166 in company stock By Investing.com", "summary": "EyePoint's Chief Medical Officer, Ramiro Ribeiro, sold $73,166 worth of company stock after exercising options. These transactions, occurring on June 30, 2026, leave Ribeiro with no direct shares but 153,564 stock options. Despite the sale, the stock currently trades below the sa", "url": "https://ca.investing.com/news/stock-market-news/eyepoint-cmo-ramiro-ribeiro-sells-73166-in-company-stock-93CH-4718901", "source_name": "Investing.com Canada", "published_at": "2026-07-02T19:42:31", "published_display": "02 Jul 2026 19:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint CMO sells 4,875 shares after option exercise | EYPT Insider Trading", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNY0lNRldrcVExMXd4UXhrZHdNXzBway1tMDFqYV9YUUhPRTVLMzlyeWJWRVlYRXZudWE3VEpUUHpWM0pCTFl6WnVzWjNIckQzQmZPTnhDdGZjR0lmT0ZpRVNKcldJSWlVY25UazhUalJkOGpQcXJCNGU5TldNQlFKLWVWOUFPMEs1bGFzaTlNcGwtY0QzZTJzbk5nS2NENVdMZXdqcVZTaE40RW8?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did Broad Russell Growth Index Additions Just Reframe EyePoint\u2019s (EYPT) Small-Cap Biotech Profile?", "summary": "EyePoint Pharmaceuticals, Inc. (EYPT) was recently added to several Russell growth indices, including the Russell 3000 Growth and 2000 Growth. This inclusion could boost the company's visibility among institutional investors and enhance liquidity, but it doesn't alter the core in", "url": "https://www.sahmcapital.com/news/content/did-broad-russell-growth-index-additions-just-reframe-eyepoints-eypt-small-cap-biotech-profile-2026-06-30", "source_name": "Sahm", "published_at": "2026-07-02T01:41:07", "published_display": "02 Jul 2026 01:41", "sentiment": "positive", "sentiment_pct": 64, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint, Inc.(NasdaqGM: EYPT) added to Russell 2500 Growth Benchmark", "summary": "EyePoint, Inc. (NasdaqGM: EYPT), a clinical-stage biopharmaceutical company focusing on treatments for serious retinal diseases, has been added to the Russell 2500 Growth Benchmark. The company's lead product candidate, DURAVYU, is currently in Phase III pivotal trials for wet ag", "url": "https://www.marketscreener.com/news/eyepoint-inc-nasdaqgm-eypt-added-to-russell-2500-growth-benchmark-ce7f5fdfda81f623", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T19:11:55", "published_display": "29 Jun 2026 19:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint, Inc.(NasdaqGM: EYPT) added to Russell 2000 Growth Benchmark", "summary": "EyePoint, Inc. (NasdaqGM: EYPT) has been added to the Russell 2000 Growth Benchmark. The company, a clinical-stage biopharmaceutical firm, is focused on developing therapeutics for serious retinal diseases, with its lead product candidate, DURAVYU, currently undergoing Phase III ", "url": "https://www.marketscreener.com/news/eyepoint-inc-nasdaqgm-eypt-added-to-russell-2000-growth-benchmark-ce7f5fdede8ff320", "source_name": "marketscreener.com", "published_at": "2026-06-29T10:37:29", "published_display": "29 Jun 2026 10:37", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EYPT Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an overview of EyePoint, Inc. (EYPT) stock performance and analyst forecasts. It includes the current stock price, historical highs and lows, market capitalization, volatility, and details on recent earnings and revenue. Analysts have provided target prices ", "url": "https://www.tradingview.com/symbols/NASDAQ-EYPT/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T11:39:29", "published_display": "27 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho reiterates EyePoint stock rating on competitor timeline shift", "summary": "Mizuho has reiterated an Outperform rating and $36.00 price target for EyePoint Inc. following news that a competitor, Ocular Therapeutix, has delayed its NDA submission timelines for a rival product. This development is seen as positive for EyePoint, which expects top-line resul", "url": "https://m.investing.com/news/analyst-ratings/mizuho-reiterates-eyepoint-stock-rating-on-competitor-timeline-shift-93CH-4755327?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-23T12:12:37", "published_display": "23 Jun 2026 12:12", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 8K Eyepoint Pharmaceuticals Inc For: 22 June By Investing.com", "summary": "This article from Investing.com announces Eyepoint Pharmaceuticals Inc.'s Form 8K filing for June 22. The publication provides general financial market data, including various indices, stock performances, and commodity prices, alongside this specific company update. It also featu", "url": "https://za.investing.com/news/stock-market-news/form-8k-eyepoint-pharmaceuticals-inc-for-22-june-93CH-4337274", "source_name": "Investing.com South Africa", "published_at": "2026-06-23T11:39:29", "published_display": "23 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint stockholders approve incentive plan amendment and elect directors", "summary": "EyePoint, Inc. stockholders approved an amendment to the company's 2023 Long-Term Incentive Plan, increasing authorized shares by 4.9 million, and elected directors at their annual meeting. Key resolutions also included the approval of executive compensation and the ratification ", "url": "https://m.investing.com/news/sec-filings/eyepoint-stockholders-approve-incentive-plan-amendment-and-elect-directors-93CH-4752333?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-22T11:09:34", "published_display": "22 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint (EYPT) investors approve 4.9M-share incentive plan increase and all 2026 AGM proposals", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPSGhxSUdwVWp2aUdZYWRSNzJuM0owNG5KcTlQYzJrS042elEyT0dqdkFyUFVJZjF0REVZcEtVVjNUbnZ4V2lZWEdxMmQ3ZVRiNzFSeGh0Ym5nd0I4WUlZZmU2cEIwZElTdVc1MzZJX1JxUHZnM05PYVhLRXJEcjdQZVZ5VnRobTBsLVZvVWpYLVloSndZN0NMSmZUNlZSQWdxb1drbQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint Pharmaceuticals Inc (EYPT) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of EyePoint Pharmaceuticals Inc (EYPT), focusing on its price momentum, support and resistance levels, and key technical indicators. The stock currently has a price momentum score of 8.91 and is trading within a range suitable for swing ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eypt/technical", "source_name": "TradingKey", "published_at": "2026-06-19T06:41:10", "published_display": "19 Jun 2026 06:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint Pharmaceuticals Inc (EYPT) Valuation: PE, PB & Fair Value Analysis", "summary": "EyePoint Pharmaceuticals Inc (EYPT) currently holds a valuation score of 6.48, placing it 149th out of 157 in the Pharmaceuticals industry. Its P/E ratio stands at -3.87, representing a significant variance from its recent highs and lows. The company has not yet disclosed relevan", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eypt/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T19:39:41", "published_display": "18 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint Pharmaceuticals Inc (EYPT) Institutional Confidence", "summary": "EyePoint Pharmaceuticals Inc (EYPT) currently holds an institutional shareholding score of 10.00, placing it first among 157 companies in the Pharmaceuticals industry. The institutional shareholding proportion is 105.59%, which is a 16.25% decrease quarter-over-quarter. James Sim", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eypt/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T19:09:35", "published_display": "18 Jun 2026 19:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint Pharmaceuticals Inc", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTFBzQVZyYUR6UFBTbVpMbEprU2dOa0NCTTdva29IYUxhV2RHMUE5V2szVVJyZWhhRHZZejlXYU94MldDMVcyLVBCQS1lclJES1k3ZE1aNEpVQ25TTjdIc0xDUFVhRmFvUHJJSVZqOEdB?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T09:27:22+00:00", "published_display": "18 Jun 2026 09:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint Pharmaceuticals Inc (EYPT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for EyePoint Pharmaceuticals Inc (EYPT), detailing its business segments and regional contributions. As of April 6, the company's Q4 FY2022 revenue shows YUTIQ as a key product segment and the United States as the dominant regional contri", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eypt/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T09:10:16", "published_display": "18 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint Pharmaceuticals Inc (EYPT) Financial Health: Profitability & Balance Sheet Analysis", "summary": "EyePoint Pharmaceuticals Inc (EYPT) currently holds a financial score of 5.96, ranking 149 out of 157 in the Pharmaceuticals industry, indicating stable financial status but low operating efficiency. The company's latest quarterly revenue decreased by 97.15% year-over-year to $69", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eypt/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T06:41:10", "published_display": "18 Jun 2026 06:41", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint Pharmaceuticals Inc (EYPT) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of EyePoint Pharmaceuticals Inc (EYPT) focusing on its dividend history and stock splits. It states that the company has not distributed any dividends over the past five years. The article also lists multiple stock merger events that occurred on ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eypt/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:09:46", "published_display": "17 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint Pharmaceuticals Inc (EYPT) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for EyePoint Pharmaceuticals Inc (EYPT), highlighting its current earnings forecast score of 8.67, which ranks 13th in the Pharmaceuticals industry. Analysts have set an average price target of $33.00, with a consensus \"Buy\" rating based", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eypt/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T06:09:47", "published_display": "17 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/eyepoint-reports-inducement-grants-under-110000426.html", "source_name": "GlobeNewswire", "published_at": "2026-06-16T11:00:00+00:00", "published_display": "16 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New hires at EyePoint receive 39,700 stock options package", "summary": "EyePoint (EYPT) granted non-statutory stock options for up to 39,700 shares of common stock to three new employees on June 15, 2026. These inducement awards were made under NASDAQ Listing Rule 5635(c)(4), with an exercise price of $12.08 per share and a ten-year term. The options", "url": "https://www.stocktitan.net/news/EYPT/eye-point-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-ca8rkaeqx4ew.html", "source_name": "Stock Titan", "published_at": "2026-06-16T10:39:00", "published_display": "16 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint Pharmaceuticals Eyes Transformative 2026 as DURAVYU Phase 3 Data Nears", "summary": "", "url": "https://finance.yahoo.com/m/49dcb5cf-4a67-383b-877c-25681e144746/eyepoint-pharmaceuticals-eyes.html", "source_name": "MarketBeat", "published_at": "2026-05-26T16:04:15+00:00", "published_display": "26 May 2026 16:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The EyePoint (EYPT) Narrative Is Evolving With DURAVYU Trials And New Analyst Targets", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNUkxzT0x0VENwMzNRR0tKRGlCZjEwc0lOSzExeGkta3BMMEdkMERuM3d6T1VMTmRMNHJfLWM0V0JyRkxwTEtReDNkZ0M1bUo2aHhDNThtSmdiZzNFaEZrckxvOUpBMHdFR3FuM3VZZVJLLUVvUl9qUVc0WGdlaWlza3diaGFLd25ydDhCVDZQSkJmR2RpWkJNd2g5V29XMmF1UDd0UFUweGs?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint Announces Participation at Upcoming Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/eyepoint-announces-participation-upcoming-investor-110000554.html", "source_name": "GlobeNewswire", "published_at": "2026-05-19T11:00:00+00:00", "published_display": "19 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint, Inc. Grants Stock Options to New Employees as Inducement Awards | EYPT Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOOW9TSFdidmNzQXdaRG5JcWdhbmx0ODdlOTgxdDNydXNSeUZaMWo2cC1mVUFtZmRnR0U1dUZUclVvT2lGRnUtLVF1THVZM19tSVNPb3lIY2FVV2k0VGxwaVpzbHJoS2cySGRQOG1VajhkZ1BzSmh6WGN2djVfWVRTRldvMWw4c1lGa25iNzVBUENZbzVGREYzSDV4OVZwOGtLS2ZhVm85UnNJVUZT?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing EyePoint (EYPT) Valuation After Recent Share Price Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPSU9WVUhSTHRLZEpJWUV5YzZvNGpLdTZnWDZSV3RQOEJtZWh1VTBPOXBpaUtkOW1iYlhMVThsUy1DWTczLVRHTU5HbFVqUDVLZDNGRzQ1M0tNMmExRWJkdW80TF94dFI4VDgzbmg4cFN0SXA3MGl3c0xXOERCTXdlVlUwd0hLUGRmS1ZzM2MyUFItYXR0Z3NyN0tBWWpIemVCMHZOZ1JrMjA?oc=5", "source_name": "Market source", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "EyePoint Pharmaceuticals Says Phase 3 Eye Drug Trials Clear Safety Review", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/eyepoint-pharmaceuticals-says-phase-3-121254882.html", "source_name": "MT Newswires", "published_at": "2026-05-14T12:12:54+00:00", "published_display": "14 May 2026 12:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "EyePoint (EYPT) Q1 Loss Near US$85 Million Tests Bullish DURAVYU Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint (EYPT) Reports Q1 Loss, Tops Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOQjZMSTN1dmF0czVlcFk5aFF4VV9CLU5HeVlZUTF5Q093SU9QSFVMZjREY000WHIxcnhIakhvbDlpYzBhN09abFFOZ2R6YjQzMzdMdzh4MTZkbkd3dVRueThJbmU3VGlBWllUUnFwcW1HOTNrckNTX1otRWJ5Wk4xdzRqZkUxS0V3Z1JnR2NtNHdWQTZHNEstdHIxSGFaTnM?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "EyePoint: The 'Pre-Readout' Surge Is Hiding A Commercial Reality Check (NASDAQ:EYPT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQc0lnUUN2MXFMWnVnZGQ4VXZSa25rb0NrTTNWNVVuT01tRUxJeEoyZzVmT0dIZHYwaU9yV1MxQnhwVEtGMDMyVkJVd1RyVTZwUHJJTzg4SzR1VlVOWDdfa0JyeHFya1Q0V1hUNkpPcmlmSUJKMHNPWWJlLXI3LTR0UkQxTDVFS1VyYWViUnBPbE5JZzdkMkV6ODBfdXpPaEwwaU0zbHcyVXIzU1Jz?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint, Inc.'s (NASDAQ:EYPT) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-04T08:00:00+00:00", "published_display": "04 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint Pharmaceuticals changes name to EyePoint, Inc., retains EYPT ticker", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOdE5iTnZTb1lBbEo4akFwWHhSZTBTRk9PNFlNWElvVkpJLWwyVmRyeE5YbG5JNWdRM2xXSlBKOWRKTVNmcWladW90eEhub19Hc0k0UUJhNmhidHNnZWotU3NyWGVjU0dzek1ndzBlUTVzZEVzR0xQLUF2c3BKa2dRS0l2UXZWMHZyR1E1eVd6alY0bGpDTVV6OTNQUWlaQ2Q0UVhFcmNKQ0g1R0dYR3hrUDlEY0FETXFsT0Fuc2hPaTFUdzMtSEtYeA?oc=5", "source_name": "Investing.com", "published_at": "2025-12-08T08:00:00+00:00", "published_display": "08 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint Pharmaceuticals Reports Positive DSMC Review for DURAVYU Clinical Trials with No Protocol Changes Recommended", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWE9aUW16WFhZNWdPM1lueF92dzRveFAwN3ZHUlVha283VWFEckRQNnJGRzNIbXZzS2ViUGs2Rm9CZ3FiejJkQ1UzRkFPVkVXWjI2T043SlFiUXFuQzVjbzNsSzJDUmpjZFZnZ0h1Z2RtUTFSUXVaWFppVlFncktHbjdpVWR2MHlmcGRubGlDTG80VjdCWkx4V1Q5V3Z3S3Vyal8xMzJsVnBabk9iNDRIMjJLd1RhVWRKOEpxTlRiZXRiWVJnNzVRbnU3cVZYY2UxbVpneV9VbDlHSGxRZXg1UHVxUEJqUQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-11-19T08:00:00+00:00", "published_display": "19 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint Pharmaceuticals (EYPT): Valuation Update Following Positive Phase 3 DURAVYU Safety Review", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOLW91UThQWXA4TDB5N29pZVduNnotc3RNb2txWXMzODRWQW4zTnhYbDZlVDI5WVVrN0N3RFotTzNSSGNxQVQzeFBNRWpRV3RLWEFqOU0zRnpsWGR6RGJTbGtQV0xCQWRaTEFPalhGSUk1LUN1bUo3ald0emp2Q1VYRVl3Q3J3cUhuNVV2OUZBOFZyLW1aZWZrRllwYw?oc=5", "source_name": "Market source", "published_at": "2025-11-19T08:00:00+00:00", "published_display": "19 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BREAKING NEWS: Alimera acquires US commercial rights to fluocinolone acetonide intravitreal insert from EyePoint Pharmaceuticals", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-wFBVV95cUxPQktHdlVpQ0VDMF90a3lhazBDS3ZZaElfeG9hUGZrbmkxWXZvd2Z6d0FNOHlzbHFCN0xGUWxvRUxTSHVlR2hqODZFeDhiNXh1YmVmMVlhVjRGdVpTWEdMcmhlMlpVQk93aEVNUktGYjRQRFNkWUZkcTdwdjdUVUNKVklnNk4tN0R6SDVmd2lLanFtZ0poMHhCWEpwaVNHdU9zUV9ydGdhVzNBcF9VTHB1YUFOcU1MVDlGMTMzclJOSHpvdHJXelJXZFFmRi00VmdvSThibk5LUlZHNG1jVjdhOVUycVNxWkhHNXlpaUhyTWN4S01GYjdDTHpuUQ?oc=5", "source_name": "Ophthalmology Times Europe", "published_at": "2023-05-18T07:00:00+00:00", "published_display": "18 May 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EYPT Stock Price and Chart \u2014 NASDAQ:EYPT", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTFBiaURCNFhUSnBvTWdQOVhQY29ERkduekxiZUx0aUc1WjJobTBkakVFY192SFB5RmFiM19JMVp5UTNxNjVnTnVfZFJyTGNacERwQ2lUMDNDQk54Tk1L?oc=5", "source_name": "TradingView", "published_at": "2023-03-29T07:00:00+00:00", "published_display": "29 Mar 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Stifel initiates EyePoint stock with buy rating on retinal drug potential", "summary": "Stifel has initiated coverage on EyePoint Inc. with a buy rating and a $40.00 price target, citing the potential of its sustained-delivery retinal disease treatment, Duravyu. The drug is expected to offer extended treatment intervals for patients with retinal diseases and its piv", "url": "https://www.investing.com/news/analyst-ratings/stifel-initiates-eyepoint-stock-with-buy-rating-on-retinal-drug-potential-93CH-4794362", "source_name": "Investing.com", "published_at": "2026-07-16T04:54:00", "published_display": "16 Jul 2026 04:54", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint, Inc. (EYPT) CEO exercises RSUs, with shares withheld for taxes", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPczJfdWZfcGJ4WnpCUjBUdDF5Z0xUQ09jX2JwcWdpOTFoZ0xBYUh4LXVOWHpUY3VpZG51a2ZNTnBHdmtoVWV1eHRTTDhZS1dlamFsLWgycks1YXgyekZXT2U2MEdiVUZ0Y2pyQUY5VlZ3YnpYekN0c1hGbjBGbW1zVGU4eTgzcTI1cTZTdDd1NzBaSDFqRnR6cUdTakV4X3pmOVdXUXlXTjFHSGs?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T20:08:19+00:00", "published_display": "14 Jul 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer", "summary": "EyePoint, Inc. appointed Tarek S. Hassan, M.D., a globally renowned retina specialist, as their Chief Strategic Science Officer. Dr. Hassan will provide strategic guidance for the company's clinical development, commercialization, and pipeline initiatives, particularly for their ", "url": "https://www.globenewswire.com/news-release/2026/07/13/3326057/0/en/eyepoint-appoints-tarek-s-hassan-m-d-as-chief-strategic-science-officer.html", "source_name": "GlobeNewswire", "published_at": "2026-07-14T04:42:14", "published_display": "14 Jul 2026 04:42", "sentiment": "positive", "sentiment_pct": 75, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint (EYPT) Adds Retina Leadership, Is The 64% Undervaluation Case Convincing?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-13T17:33:50+00:00", "published_display": "13 Jul 2026 17:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho Securities Maintains EyePoint(EYPT.US) With Buy Rating, Maintains Target Price $36", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQeWJSZVowMnFXSFR5ZEx3aGYyd1VPNVVQQ0doU2VXRXEtWGZGb2QwWGFaZDVuVTlFaE9YQ2V3aEYxTldDR0xIUWlRcTVJWkVUd05hMTJ6UDhrNTlnRTIzV1NiRXRkSHZZNzNZNjJGbW1vRWE3QS00ZE4yZTJjZ2R2VzZMNkxVcGMtS3RUUzFGbUhNQWdiWWUzbGdUeUlsN2Y1M3liNEpOZmJkZlQwZ2pjb1N6U2JBU2l1R3c?oc=5", "source_name": "Moomoo", "published_at": "2026-07-13T13:34:00+00:00", "published_display": "13 Jul 2026 13:34", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Renowned retina specialist Tarek S. Hassan joins EyePoint ahead of key DURAVYU trial readout", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQdEhfcEZkSUFxOGZkM3ZxM1ItUHpibmRGQWlLeWU4QnZ2TjEyWWFodWZyN2tUWUdqanJlS3ZjMXhfYzZJNkg3TFNOS2UyQ1o0YmVsY3pfUzRldXRzME9iNW1OYUo2M1RLNEpjRzdJNHd6VTZfb0ZROGpyWUZFenVjb2NMTW5lUTNpSFNYa2VJMUtkZVQ3NnVNSUZDajlwOGFVek5malhmaUtyLVVWdk9ET0k5eVhqRFN1c2xF?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T11:00:00+00:00", "published_display": "13 Jul 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does EyePoint\u2019s (EYPT) Broad Russell Index Debut Quietly Recast Its DURAVYU\u2011Centric Investor Base?", "summary": "EyePoint (EYPT) was recently added to several Russell growth and small-cap indices, increasing its visibility to index-tracking investors. While this broadens exposure, the company's investment narrative still heavily relies on the success of its single asset, DURAVYU, with criti", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint/news/does-eyepoints-eypt-broad-russell-index-debut-quietly-recast/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-10T16:10:10", "published_display": "10 Jul 2026 16:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint Pharmaceuticals Coverage Assumed by Cantor Fitzgerald at Overweight", "summary": "Cantor Fitzgerald has initiated coverage on EyePoint Pharmaceuticals (NASDAQ: EYPT) with an Overweight rating. The firm set a price target of $24.00 for the pharmaceutical company.", "url": "https://www.moomoo.com/news/post/72654158/eyepoint-pharmaceuticals-coverage-assumed-by-cantor-fitzgerald-at-overweight", "source_name": "Moomoo", "published_at": "2026-07-09T03:10:10", "published_display": "09 Jul 2026 03:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint Pharmaceuticals updates its strategy as retinal pipeline advances", "summary": "EyePoint Pharmaceuticals is updating its strategy as its pipeline of long-acting eye therapies for retinal diseases advances. The company specializes in sustained intraocular drug delivery, aiming to reduce treatment burden for patients. Its focus is on developing proprietary imp", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/eyepoint-pharmaceuticals-updates-its-strategy-as-retinal-pipeline-advances/69726713", "source_name": "Ad Hoc News", "published_at": "2026-07-09T03:09:47", "published_display": "09 Jul 2026 03:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price-Driven Insight from (EYPT) for Rule-Based Strategy", "summary": "This article provides a price-driven analysis for Eyepoint Pharmaceuticals Inc. (NASDAQ: EYPT), indicating a near-term neutral sentiment amidst mid and long-term strength. It outlines various AI-generated trading strategies including position, momentum breakout, and risk hedging,", "url": "https://news.stocktradersdaily.com/news_release/24/Price-Driven_Insight_from_EYPT_for_Rule-Based_Strategy_070726063802_1783420682.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-07T06:38:51", "published_display": "07 Jul 2026 06:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint shared additions to scientific advisory board and conditional approval of trade name for EYP-1901", "summary": "EyePoint Pharmaceuticals has expanded its Scientific Advisory Board by appointing three leading ophthalmologists: Usha Chakravarthy, Allen Ho, and Frank Holz. These additions will support the company's global clinical strategy as it prepares for Phase 3 trials for wet age-related", "url": "https://www.ophthalmologytimes.com/view/eyepoint-shared-additions-to-scientific-advisory-board-and-conditional-approval-of-trade-name-for-eyp-1901", "source_name": "Ophthalmology Times Europe", "published_at": "2026-07-07T03:10:10", "published_display": "07 Jul 2026 03:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s Why EyePoint, Inc. (EYPT) Is Among the Best Get Rich Quick Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQTl9faU9Kd2RlckhrZEg0cFBhSDQzaVFKaW5nWkVkXzVOci1VUGxOME5xc1dzM2pvcl9iaHFEZFgwOHFwNXozMFZVNU00R0ZVU0hnaDRBOFB4Q2lGV3QwazlpaENrY1pPMGJMOGwtcGFCR0ZZUFJFcVZzY3dnYzhHMGx2OWJMQ2puR3c0UFhaT1dZR09tTmxn?oc=5", "source_name": "Market source", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Guggenheim reiterates Buy on EyePoint stock, cites trial progress", "summary": "Guggenheim has reiterated a Buy rating on EyePoint Inc. (NASDAQ:EYPT) with a $68.00 price target, citing promising progress in the company's clinical trials for wet age-related macular degeneration and diabetic macular edema. Enrollment is complete for the LUGANO and LUCIA trials", "url": "https://www.investing.com/news/analyst-ratings/guggenheim-reiterates-buy-on-eyepoint-stock-cites-trial-progress-93CH-4666411", "source_name": "Investing.com", "published_at": "2026-07-06T02:10:36", "published_display": "06 Jul 2026 02:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint Pharmaceuticals outlines long-term retina strategy as a specialty biotech", "summary": "EyePoint Pharmaceuticals is a specialty biopharmaceutical company focused on developing sustained drug delivery technologies for serious retinal diseases. The company aims to address the burden of frequent treatments for conditions like age-related macular degeneration by providi", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/eyepoint-pharmaceuticals-outlines-long-term-retina-strategy-as-a-specialty/69682599", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T19:09:13", "published_display": "03 Jul 2026 19:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint (EYPT) Joins Russell Growth Indices, Is The Stock Still Undervalued?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-03T12:29:46+00:00", "published_display": "03 Jul 2026 12:29", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Eyepoint Pharmaceuticals Inc For: 2 July By Investing.com", "summary": "This article reports on a Form 4 filing for Eyepoint Pharmaceuticals Inc. for transactions that occurred on July 2nd. It is a brief announcement from Investing.com and does not contain further details within the main body. The article is surrounded by various financial market dat", "url": "https://ca.investing.com/news/stock-market-news/form-4-eyepoint-pharmaceuticals-inc-for-2-july-93CH-4718918", "source_name": "Investing.com Canada", "published_at": "2026-07-02T20:42:31", "published_display": "02 Jul 2026 20:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint CMO Ramiro Ribeiro sells $73,166 in company stock", "summary": "EyePoint, Inc.'s Chief Medical Officer, Ramiro Ribeiro, recently sold 4,875 shares of company stock, totaling approximately $73,166, after exercising stock options. Following these transactions, Ribeiro holds no direct shares but retains 153,564 stock options. The company is repo", "url": "https://www.investing.com/news/insider-trading-news/eyepoint-cmo-ramiro-ribeiro-sells-73166-in-company-stock-93CH-4774038", "source_name": "Investing.com", "published_at": "2026-07-02T20:40:38", "published_display": "02 Jul 2026 20:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint CMO Ramiro Ribeiro sells $73,166 in company stock By Investing.com", "summary": "EyePoint's Chief Medical Officer, Ramiro Ribeiro, sold $73,166 worth of company stock after exercising options. These transactions, occurring on June 30, 2026, leave Ribeiro with no direct shares but 153,564 stock options. Despite the sale, the stock currently trades below the sa", "url": "https://ca.investing.com/news/stock-market-news/eyepoint-cmo-ramiro-ribeiro-sells-73166-in-company-stock-93CH-4718901", "source_name": "Investing.com Canada", "published_at": "2026-07-02T19:42:31", "published_display": "02 Jul 2026 19:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint CMO sells 4,875 shares after option exercise | EYPT Insider Trading", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNY0lNRldrcVExMXd4UXhrZHdNXzBway1tMDFqYV9YUUhPRTVLMzlyeWJWRVlYRXZudWE3VEpUUHpWM0pCTFl6WnVzWjNIckQzQmZPTnhDdGZjR0lmT0ZpRVNKcldJSWlVY25UazhUalJkOGpQcXJCNGU5TldNQlFKLWVWOUFPMEs1bGFzaTlNcGwtY0QzZTJzbk5nS2NENVdMZXdqcVZTaE40RW8?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did Broad Russell Growth Index Additions Just Reframe EyePoint\u2019s (EYPT) Small-Cap Biotech Profile?", "summary": "EyePoint Pharmaceuticals, Inc. (EYPT) was recently added to several Russell growth indices, including the Russell 3000 Growth and 2000 Growth. This inclusion could boost the company's visibility among institutional investors and enhance liquidity, but it doesn't alter the core in", "url": "https://www.sahmcapital.com/news/content/did-broad-russell-growth-index-additions-just-reframe-eyepoints-eypt-small-cap-biotech-profile-2026-06-30", "source_name": "Sahm", "published_at": "2026-07-02T01:41:07", "published_display": "02 Jul 2026 01:41", "sentiment": "positive", "sentiment_pct": 64, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint, Inc.(NasdaqGM: EYPT) added to Russell 2500 Growth Benchmark", "summary": "EyePoint, Inc. (NasdaqGM: EYPT), a clinical-stage biopharmaceutical company focusing on treatments for serious retinal diseases, has been added to the Russell 2500 Growth Benchmark. The company's lead product candidate, DURAVYU, is currently in Phase III pivotal trials for wet ag", "url": "https://www.marketscreener.com/news/eyepoint-inc-nasdaqgm-eypt-added-to-russell-2500-growth-benchmark-ce7f5fdfda81f623", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T19:11:55", "published_display": "29 Jun 2026 19:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint, Inc.(NasdaqGM: EYPT) added to Russell 2000 Growth Benchmark", "summary": "EyePoint, Inc. (NasdaqGM: EYPT) has been added to the Russell 2000 Growth Benchmark. The company, a clinical-stage biopharmaceutical firm, is focused on developing therapeutics for serious retinal diseases, with its lead product candidate, DURAVYU, currently undergoing Phase III ", "url": "https://www.marketscreener.com/news/eyepoint-inc-nasdaqgm-eypt-added-to-russell-2000-growth-benchmark-ce7f5fdede8ff320", "source_name": "marketscreener.com", "published_at": "2026-06-29T10:37:29", "published_display": "29 Jun 2026 10:37", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EYPT Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an overview of EyePoint, Inc. (EYPT) stock performance and analyst forecasts. It includes the current stock price, historical highs and lows, market capitalization, volatility, and details on recent earnings and revenue. Analysts have provided target prices ", "url": "https://www.tradingview.com/symbols/NASDAQ-EYPT/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T11:39:29", "published_display": "27 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho reiterates EyePoint stock rating on competitor timeline shift", "summary": "Mizuho has reiterated an Outperform rating and $36.00 price target for EyePoint Inc. following news that a competitor, Ocular Therapeutix, has delayed its NDA submission timelines for a rival product. This development is seen as positive for EyePoint, which expects top-line resul", "url": "https://m.investing.com/news/analyst-ratings/mizuho-reiterates-eyepoint-stock-rating-on-competitor-timeline-shift-93CH-4755327?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-23T12:12:37", "published_display": "23 Jun 2026 12:12", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 8K Eyepoint Pharmaceuticals Inc For: 22 June By Investing.com", "summary": "This article from Investing.com announces Eyepoint Pharmaceuticals Inc.'s Form 8K filing for June 22. The publication provides general financial market data, including various indices, stock performances, and commodity prices, alongside this specific company update. It also featu", "url": "https://za.investing.com/news/stock-market-news/form-8k-eyepoint-pharmaceuticals-inc-for-22-june-93CH-4337274", "source_name": "Investing.com South Africa", "published_at": "2026-06-23T11:39:29", "published_display": "23 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint stockholders approve incentive plan amendment and elect directors", "summary": "EyePoint, Inc. stockholders approved an amendment to the company's 2023 Long-Term Incentive Plan, increasing authorized shares by 4.9 million, and elected directors at their annual meeting. Key resolutions also included the approval of executive compensation and the ratification ", "url": "https://m.investing.com/news/sec-filings/eyepoint-stockholders-approve-incentive-plan-amendment-and-elect-directors-93CH-4752333?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-22T11:09:34", "published_display": "22 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint (EYPT) investors approve 4.9M-share incentive plan increase and all 2026 AGM proposals", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPSGhxSUdwVWp2aUdZYWRSNzJuM0owNG5KcTlQYzJrS042elEyT0dqdkFyUFVJZjF0REVZcEtVVjNUbnZ4V2lZWEdxMmQ3ZVRiNzFSeGh0Ym5nd0I4WUlZZmU2cEIwZElTdVc1MzZJX1JxUHZnM05PYVhLRXJEcjdQZVZ5VnRobTBsLVZvVWpYLVloSndZN0NMSmZUNlZSQWdxb1drbQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint Pharmaceuticals Inc (EYPT) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of EyePoint Pharmaceuticals Inc (EYPT), focusing on its price momentum, support and resistance levels, and key technical indicators. The stock currently has a price momentum score of 8.91 and is trading within a range suitable for swing ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eypt/technical", "source_name": "TradingKey", "published_at": "2026-06-19T06:41:10", "published_display": "19 Jun 2026 06:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint Pharmaceuticals Inc (EYPT) Valuation: PE, PB & Fair Value Analysis", "summary": "EyePoint Pharmaceuticals Inc (EYPT) currently holds a valuation score of 6.48, placing it 149th out of 157 in the Pharmaceuticals industry. Its P/E ratio stands at -3.87, representing a significant variance from its recent highs and lows. The company has not yet disclosed relevan", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eypt/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T19:39:41", "published_display": "18 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint Pharmaceuticals Inc (EYPT) Institutional Confidence", "summary": "EyePoint Pharmaceuticals Inc (EYPT) currently holds an institutional shareholding score of 10.00, placing it first among 157 companies in the Pharmaceuticals industry. The institutional shareholding proportion is 105.59%, which is a 16.25% decrease quarter-over-quarter. James Sim", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eypt/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T19:09:35", "published_display": "18 Jun 2026 19:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint Pharmaceuticals Inc", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTFBzQVZyYUR6UFBTbVpMbEprU2dOa0NCTTdva29IYUxhV2RHMUE5V2szVVJyZWhhRHZZejlXYU94MldDMVcyLVBCQS1lclJES1k3ZE1aNEpVQ25TTjdIc0xDUFVhRmFvUHJJSVZqOEdB?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T09:27:22+00:00", "published_display": "18 Jun 2026 09:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint Pharmaceuticals Inc (EYPT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for EyePoint Pharmaceuticals Inc (EYPT), detailing its business segments and regional contributions. As of April 6, the company's Q4 FY2022 revenue shows YUTIQ as a key product segment and the United States as the dominant regional contri", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eypt/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T09:10:16", "published_display": "18 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint Pharmaceuticals Inc (EYPT) Financial Health: Profitability & Balance Sheet Analysis", "summary": "EyePoint Pharmaceuticals Inc (EYPT) currently holds a financial score of 5.96, ranking 149 out of 157 in the Pharmaceuticals industry, indicating stable financial status but low operating efficiency. The company's latest quarterly revenue decreased by 97.15% year-over-year to $69", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eypt/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T06:41:10", "published_display": "18 Jun 2026 06:41", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint Pharmaceuticals Inc (EYPT) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of EyePoint Pharmaceuticals Inc (EYPT) focusing on its dividend history and stock splits. It states that the company has not distributed any dividends over the past five years. The article also lists multiple stock merger events that occurred on ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eypt/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:09:46", "published_display": "17 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint Pharmaceuticals Inc (EYPT) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for EyePoint Pharmaceuticals Inc (EYPT), highlighting its current earnings forecast score of 8.67, which ranks 13th in the Pharmaceuticals industry. Analysts have set an average price target of $33.00, with a consensus \"Buy\" rating based", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eypt/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T06:09:47", "published_display": "17 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/eyepoint-reports-inducement-grants-under-110000426.html", "source_name": "GlobeNewswire", "published_at": "2026-06-16T11:00:00+00:00", "published_display": "16 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New hires at EyePoint receive 39,700 stock options package", "summary": "EyePoint (EYPT) granted non-statutory stock options for up to 39,700 shares of common stock to three new employees on June 15, 2026. These inducement awards were made under NASDAQ Listing Rule 5635(c)(4), with an exercise price of $12.08 per share and a ten-year term. The options", "url": "https://www.stocktitan.net/news/EYPT/eye-point-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-ca8rkaeqx4ew.html", "source_name": "Stock Titan", "published_at": "2026-06-16T10:39:00", "published_display": "16 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint Pharmaceuticals Eyes Transformative 2026 as DURAVYU Phase 3 Data Nears", "summary": "", "url": "https://finance.yahoo.com/m/49dcb5cf-4a67-383b-877c-25681e144746/eyepoint-pharmaceuticals-eyes.html", "source_name": "MarketBeat", "published_at": "2026-05-26T16:04:15+00:00", "published_display": "26 May 2026 16:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The EyePoint (EYPT) Narrative Is Evolving With DURAVYU Trials And New Analyst Targets", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNUkxzT0x0VENwMzNRR0tKRGlCZjEwc0lOSzExeGkta3BMMEdkMERuM3d6T1VMTmRMNHJfLWM0V0JyRkxwTEtReDNkZ0M1bUo2aHhDNThtSmdiZzNFaEZrckxvOUpBMHdFR3FuM3VZZVJLLUVvUl9qUVc0WGdlaWlza3diaGFLd25ydDhCVDZQSkJmR2RpWkJNd2g5V29XMmF1UDd0UFUweGs?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint Announces Participation at Upcoming Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/eyepoint-announces-participation-upcoming-investor-110000554.html", "source_name": "GlobeNewswire", "published_at": "2026-05-19T11:00:00+00:00", "published_display": "19 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint, Inc. Grants Stock Options to New Employees as Inducement Awards | EYPT Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOOW9TSFdidmNzQXdaRG5JcWdhbmx0ODdlOTgxdDNydXNSeUZaMWo2cC1mVUFtZmRnR0U1dUZUclVvT2lGRnUtLVF1THVZM19tSVNPb3lIY2FVV2k0VGxwaVpzbHJoS2cySGRQOG1VajhkZ1BzSmh6WGN2djVfWVRTRldvMWw4c1lGa25iNzVBUENZbzVGREYzSDV4OVZwOGtLS2ZhVm85UnNJVUZT?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing EyePoint (EYPT) Valuation After Recent Share Price Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPSU9WVUhSTHRLZEpJWUV5YzZvNGpLdTZnWDZSV3RQOEJtZWh1VTBPOXBpaUtkOW1iYlhMVThsUy1DWTczLVRHTU5HbFVqUDVLZDNGRzQ1M0tNMmExRWJkdW80TF94dFI4VDgzbmg4cFN0SXA3MGl3c0xXOERCTXdlVlUwd0hLUGRmS1ZzM2MyUFItYXR0Z3NyN0tBWWpIemVCMHZOZ1JrMjA?oc=5", "source_name": "Market source", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint Pharmaceuticals Says Phase 3 Eye Drug Trials Clear Safety Review", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/eyepoint-pharmaceuticals-says-phase-3-121254882.html", "source_name": "MT Newswires", "published_at": "2026-05-14T12:12:54+00:00", "published_display": "14 May 2026 12:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint (EYPT) Q1 Loss Near US$85 Million Tests Bullish DURAVYU Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint (EYPT) Reports Q1 Loss, Tops Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOQjZMSTN1dmF0czVlcFk5aFF4VV9CLU5HeVlZUTF5Q093SU9QSFVMZjREY000WHIxcnhIakhvbDlpYzBhN09abFFOZ2R6YjQzMzdMdzh4MTZkbkd3dVRueThJbmU3VGlBWllUUnFwcW1HOTNrckNTX1otRWJ5Wk4xdzRqZkUxS0V3Z1JnR2NtNHdWQTZHNEstdHIxSGFaTnM?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint: The 'Pre-Readout' Surge Is Hiding A Commercial Reality Check (NASDAQ:EYPT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQc0lnUUN2MXFMWnVnZGQ4VXZSa25rb0NrTTNWNVVuT01tRUxJeEoyZzVmT0dIZHYwaU9yV1MxQnhwVEtGMDMyVkJVd1RyVTZwUHJJTzg4SzR1VlVOWDdfa0JyeHFya1Q0V1hUNkpPcmlmSUJKMHNPWWJlLXI3LTR0UkQxTDVFS1VyYWViUnBPbE5JZzdkMkV6ODBfdXpPaEwwaU0zbHcyVXIzU1Jz?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint, Inc.'s (NASDAQ:EYPT) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-04T08:00:00+00:00", "published_display": "04 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint Pharmaceuticals changes name to EyePoint, Inc., retains EYPT ticker", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOdE5iTnZTb1lBbEo4akFwWHhSZTBTRk9PNFlNWElvVkpJLWwyVmRyeE5YbG5JNWdRM2xXSlBKOWRKTVNmcWladW90eEhub19Hc0k0UUJhNmhidHNnZWotU3NyWGVjU0dzek1ndzBlUTVzZEVzR0xQLUF2c3BKa2dRS0l2UXZWMHZyR1E1eVd6alY0bGpDTVV6OTNQUWlaQ2Q0UVhFcmNKQ0g1R0dYR3hrUDlEY0FETXFsT0Fuc2hPaTFUdzMtSEtYeA?oc=5", "source_name": "Investing.com", "published_at": "2025-12-08T08:00:00+00:00", "published_display": "08 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint Pharmaceuticals Reports Positive DSMC Review for DURAVYU Clinical Trials with No Protocol Changes Recommended", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWE9aUW16WFhZNWdPM1lueF92dzRveFAwN3ZHUlVha283VWFEckRQNnJGRzNIbXZzS2ViUGs2Rm9CZ3FiejJkQ1UzRkFPVkVXWjI2T043SlFiUXFuQzVjbzNsSzJDUmpjZFZnZ0h1Z2RtUTFSUXVaWFppVlFncktHbjdpVWR2MHlmcGRubGlDTG80VjdCWkx4V1Q5V3Z3S3Vyal8xMzJsVnBabk9iNDRIMjJLd1RhVWRKOEpxTlRiZXRiWVJnNzVRbnU3cVZYY2UxbVpneV9VbDlHSGxRZXg1UHVxUEJqUQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-11-19T08:00:00+00:00", "published_display": "19 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EyePoint Pharmaceuticals (EYPT): Valuation Update Following Positive Phase 3 DURAVYU Safety Review", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOLW91UThQWXA4TDB5N29pZVduNnotc3RNb2txWXMzODRWQW4zTnhYbDZlVDI5WVVrN0N3RFotTzNSSGNxQVQzeFBNRWpRV3RLWEFqOU0zRnpsWGR6RGJTbGtQV0xCQWRaTEFPalhGSUk1LUN1bUo3ald0emp2Q1VYRVl3Q3J3cUhuNVV2OUZBOFZyLW1aZWZrRllwYw?oc=5", "source_name": "Market source", "published_at": "2025-11-19T08:00:00+00:00", "published_display": "19 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BREAKING NEWS: Alimera acquires US commercial rights to fluocinolone acetonide intravitreal insert from EyePoint Pharmaceuticals", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-wFBVV95cUxPQktHdlVpQ0VDMF90a3lhazBDS3ZZaElfeG9hUGZrbmkxWXZvd2Z6d0FNOHlzbHFCN0xGUWxvRUxTSHVlR2hqODZFeDhiNXh1YmVmMVlhVjRGdVpTWEdMcmhlMlpVQk93aEVNUktGYjRQRFNkWUZkcTdwdjdUVUNKVklnNk4tN0R6SDVmd2lLanFtZ0poMHhCWEpwaVNHdU9zUV9ydGdhVzNBcF9VTHB1YUFOcU1MVDlGMTMzclJOSHpvdHJXelJXZFFmRi00VmdvSThibk5LUlZHNG1jVjdhOVUycVNxWkhHNXlpaUhyTWN4S01GYjdDTHpuUQ?oc=5", "source_name": "Ophthalmology Times Europe", "published_at": "2023-05-18T07:00:00+00:00", "published_display": "18 May 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EYPT Stock Price and Chart \u2014 NASDAQ:EYPT", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTFBiaURCNFhUSnBvTWdQOVhQY29ERkduekxiZUx0aUc1WjJobTBkakVFY192SFB5RmFiM19JMVp5UTNxNjVnTnVfZFJyTGNacERwQ2lUMDNDQk54Tk1L?oc=5", "source_name": "TradingView", "published_at": "2023-03-29T07:00:00+00:00", "published_display": "29 Mar 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 99, "total_relevant": 61, "sentiment_summary": {"positive": 22, "negative": 4, "neutral": 35, "score": 57, "total": 61, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 20.15, "count": 36}, {"event": "earnings", "label": "Earnings", "weight": 6.05, "count": 13}, {"event": "analyst", "label": "Analyst action", "weight": 3.3, "count": 6}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 22, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 14.72, "latest_week": "2026-07-10", "one_week_move": 5.3, "four_week_move": 13.0, "twelve_week_move": -1.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.528642, "market_dynamics_buy_signal": false, "relative_strength": -7.424988, "fair_value_gap": 19.9, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 49.9757, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+5.3% over one week, +13.0% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 67, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 10}, {"label": "TradingKey", "count": 8}, {"label": "Investing.com", "count": 6}, {"label": "simplywall.st", "count": 6}, {"label": "Stock Titan", "count": 5}, {"label": "GlobeNewswire", "count": 3}, {"label": "TradingView", "count": 3}, {"label": "Moomoo", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 53}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 36}, {"label": "Earnings", "count": 13}, {"label": "Analyst action", "count": 6}, {"label": "Regulatory and legal", "count": 2}, {"label": "Guidance", "count": 1}, {"label": "Balance sheet", "count": 1}, {"label": "Macro sensitivity", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "53", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+5.3% over one week, +13.0% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Stifel initiates EyePoint stock with buy rating on retinal drug potential"}], "updated_at": "2026-07-16T08:07:37.768855+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}